BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.
Last trade$1.98
Day change$0.00 (0.00%)
Day range$1.92 – $2.08
Volume179,804
Market cap$159M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$158.9M
Price / earnings
—
Price / book
0.54×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.44×
Profitability
Earnings per share
-$2.14
Return on assets
-49.54%
Return on equity
-58.47%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
4.08×
Quick ratio
4.08×
Cash ratio
1.5×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$151.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BBOT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Revenue
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
Selling, general and administrative
$7.9M
$10.96M
$6.38M
$5.33M
$14.13M
Research and development
$29.59M
$49.23M
$39.8M
$38.07M
$35.05M
Total operating expenses
$37.49M
$60.19M
$46.18M
$43.41M
$49.18M
Operating income
-$37.49M
-$60.19M
-$46.18M
-$43.41M
-$49.18M
Interest expense
$0
$0
$0
$0
$0
Income before taxes
-$34.18M
-$56.45M
-$42.11M
-$38.8M
-$44.76M
Income taxes
$0
$0
$0
$0
$0
Net income
-$34.18M
-$56.45M
-$42.11M
-$38.8M
-$44.76M
Net income attributable to common shareholders
-$34.18M
-$56.45M
-$42.11M
-$38.8M
-$44.76M
EBITDA
-$37.3M
-$60M
-$45.99M
-$42.99M
-$49M
Basic earnings per share
-$0.43
-$705.20
-$526.11
-$0.48
-$1.03
Diluted earnings per share
-$0.43
-$705.20
-$526.11
-$0.48
-$1.03
Recent news
Company coverage with links to the original publishers.
BridgeBio Oncology Therapeutics announced two poster presentations for BBO-10203, a novel small molecule targeting RAS and PI3Kα interactions in cancer treatment, at the San Antonio Breast Cancer Symposium in December 2025.
BridgeBio Oncology Therapeutics presented preclinical data on BBO-10203, a novel RAS:PI3Kα breaker that inhibits KRAS-mutant tumor growth without causing hyperglycemia, showing promising results in monotherapy and combination treatments with KRAS inhibitors.
BridgeBio Oncology Therapeutics (BBOT) announced participation in two investor conferences in September, focusing on presenting their clinical-stage biopharmaceutical work targeting RAS-pathway malignancies.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.